Deep Tide TechFlow News, on August 21, according to an announcement from the U.S. Securities and Exchange Commission (SEC), due to failing to meet the minimum bid price maintenance standards (Rule 5550(a)(2)), the NASDAQ stock exchange will suspend trading of BNB Treasury Company Windtree Therapeutics (WINT) at the opening on August 21, 2025, and will delist its common stock from the NASDAQ Capital Market.
Windtree Therapeutics stated that its common stock will begin trading on the same day in the over-the-counter market (OTC Markets), with the trading code remaining "WINT" unchanged. The company has applied for trading at the OTCID tier, but has not yet received confirmation. The company emphasized that the transition to the over-the-counter market will not affect its business operations and will continue to submit periodic reports and other necessary documents to the SEC in accordance with federal securities laws.
In previous news, Windtree Therapeutics had announced plans to raise up to $520 million through equity financing, of which 99% will be used to purchase BNB. It is reported that Windtree Therapeutics is a clinical-stage biopharmaceutical and medical device company.